Page 131 - Mployee Wellness Programs News Today

Frexalimab, a Sanofi drug candidate with roots at Dartmouth’s medical school, has met the main goal of its Phase 2 test. The encouraging data for this program come as different experimental Sanofi MS drug nears its one-year anniversary under FDA clinical hold.

While retailers already have a customer service focus, there is a steep learning curve to healthcare and the nuances of how things operate. It will be critical that these brands do their due diligence and invest in innovations that work to improve the fundamentals of healthcare such as efficient provider credentialing and flexible and sustainable working practices for providers.

While these are key benefits of digital therapeutics and this optimism may have been laudable, this approach to market relies on promise without proof of efficacy and ignores the fact that not all digital therapeutics are created equal.

In addition to reducing workload, NLP and ambient voice technology can also improve the quality of care that clinicians provide. By analyzing EHRs and other patient data, NLP algorithms can identify potential health risk factors and recommend preventative measures.

Employers have a responsibility to support the food as medicine movement and help employees who are food insecure, said Jay Bhatt, managing director of Deloitte Services and managing director of the Center for Health Solutions and Health Equity Institute. He made these comments last week at the MedCity INVEST conference in Chicago.

Marstacimab, a Pfizer drug for both hemophilia A and B, met the main goal of a Phase 3 study and the company now plans to discuss the data with regulators. The Pfizer drug could beat to the market a Novo Nordisk drug that addresses the same novel target.

About 68% of Americans believe employer-sponsored insurance is important for employee recruitment and 77% believe it’s important for retention, according to a new AHIP survey. 

Compared to government payers, commercial payers take significantly longer to pay hospitals and deny claims at a higher frequency — often without a justifiable reason to do so — according to a new report. Commerical payers have better reimbursement rates than government payers, but providers often have to wait 90 days or more get claims paid by commercial plans.

Ray Therapeutics’ gene therapy is independent of the causative genes driving inherited vision disorders, which CEO Paul Bresge says is important for reaching a broad patient population. Rare disease retinitis pigmentosa is the first disease target, but the startup also plans to test its approach in more prevalent eye disorders.

A conversation with Suchi Saria, associate professor of medicine at John Hopkins University and director of its Machine Learning and Healthcare Lab about responsible AI.